HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

424.614

+0.7850.19%

Number of Gainers:17

Number of Losers:12

Number of Flat:5

PE:- -

High:428.338

Open:424.213

Low:419.152

Close:423.829

Loading ...

BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients With Ntrk-Positive Solid Tumors

THOMSON REUTERS

Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial

MT Newswires Live

BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23

Akeso - Nmpa Approved Nda of Ebdarokimab, Il-12/Il-23

THOMSON REUTERS

BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis

Akeso: Ebdarokimab Approved in China for Moderate - to - Severe Plaque Psoriasis

THOMSON REUTERS

Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal

MT Newswires Live

BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma

Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand

THOMSON REUTERS

Peijia Medical's TaurusTrio TAV System Gets Approval for Registration in China

MT Newswires Live

Peijia Medical Says NMPA Accepted Registration Application For TaurustrioTM TAV System

HBM Plans Up to HK$200 Million Share Buyback; Shares Surge 12%

MT Newswires Live

Is TOT BIOPHARM International (HKG:1875) A Risky Investment?

Simply Wall St.

BRIEF-HBM Holdings Intends To Repurchase Shares Of Co

Hbm Holdings - Intends to Repurchase Shares of Co in Open Market From Time to Time up to HK$200 Mln

THOMSON REUTERS

Peijia Medical Gets China Nod for Registration of YonFlow Stent

MT Newswires Live

Harbour Biomed Appoints Youchen Chen as Chief Financial Officer

THOMSON REUTERS

BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of Stent

Suzhou Basecare Medical Gets Jiangsu Nod for Registration of Sperm Quality Analyzer

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":424.61395,"timestamp":1744877287948,"preClose":423.82935,"halted":0,"volume":90030948,"delay":0,"changeRate":0.001851,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0.784607,"latestTime":"04-17 16:00:00","open":424.21304,"high":428.33752,"low":419.15207,"amount":2132232009,"amplitude":0.021673,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"pbRate":3.545304,"peRate":-21.142926,"turnoverRate":0.003393,"increases":15,"decrements":13,"flats":5,"marketCap":245120988800,"floatMarketCap":226797153360},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":428.33752,"amplitude":0.021673,"preClose":423.82935,"low":419.15207,"pbRate":"3.545304","latestPrice":424.61395,"volume":90030948,"delay":0,"open":424.21304,"prevYearClose":331.1933,"prevWeekClose":424.614,"prevMonthClose":455.082,"prevQuarterClose":455.082,"fiveDayClose":394.248,"twentyDayClose":449.702,"sixtyDayClose":314.993,"secType":"PLATE","market":"HK","turnoverRate":0.003393,"peRate":-21.142926,"marketCap":245120988800,"floatMarketCap":226797153360,"timestamp":1744877287948,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":12,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529146870","title":"BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2529146870","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529146870?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:49","pubTimestamp":1745236155,"startTime":"0","endTime":"0","summary":"BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid TumorsApril 21 (Reuters) - Zai Lab Ltd 9688.HK:ZAI LAB ANNOUNCES ACCEPTA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8V4FXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1588","09688","LU2488822045.USD"],"gpt_icon":0},{"id":"2529877982","title":"Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients With Ntrk-Positive Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2529877982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529877982?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:30","pubTimestamp":1745235000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8V4FXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","09688","BK1161","LU2488822045.USD","BK1574"],"gpt_icon":0},{"id":"2529874657","title":"Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874657?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:58","pubTimestamp":1745233118,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  has enrolled the first patient in the phase III clinical trial of Cyclosporine  Ophthalmic Gel, an April 17 Hong Kong bourse filing said.The ophthalmic pharmaceutical company is testing the drug for the treatment of moderate to severe dry eye disease.The trial will involve 25 centers and enroll a total of 360 patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06622","BK1583","BK1587","BK1191"],"gpt_icon":0},{"id":"2529879804","title":"BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879804?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:27","pubTimestamp":1745231265,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23April 21 (Reuters) - Akeso 9926.HK:NMPA APPROVED NDA OF EBDAROKIMAB, IL-12/IL-23Further company coverage: 9926.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0348783233.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU2488822045.USD","09926","LU0348784397.USD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1161","LU0417516571.SGD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2529769878","title":"Akeso - Nmpa Approved Nda of Ebdarokimab, Il-12/Il-23","url":"https://stock-news.laohu8.com/highlight/detail?id=2529769878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529769878?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:15","pubTimestamp":1745230511,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","LU1720050803.USD","LU0348783233.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0417516571.SGD","BK1161","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2488822045.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2528067496","title":"BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2528067496","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528067496?lang=en_us&edition=fundamental","pubTime":"2025-04-18 22:18","pubTimestamp":1744985903,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque PsoriasisApril 18 (Reuters) - Akeso Inc 9926.HK:AKESO: EBDAROKIMAB APPROVED IN CHINA FOR MODERATE - TO - SEVERE PLAQUE PSORI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nFWN3QV3AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","IE00B5MMRT66.SGD","09926","LU0348783233.USD","LU0417516571.SGD","LU2488822045.USD","BK1161","LU0348784397.USD","LU1720050803.USD","LU1794554557.SGD","IE00BPRC5H50.USD","BK1574"],"gpt_icon":0},{"id":"2528063865","title":"Akeso: Ebdarokimab Approved in China for Moderate - to - Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2528063865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528063865?lang=en_us&edition=fundamental","pubTime":"2025-04-18 19:42","pubTimestamp":1744976541,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nFWN3QV3AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","BK1161","IE00B5MMRT66.SGD","LU0348783233.USD","09926","LU2488822045.USD","LU0417516571.SGD","LU1720050803.USD","BK1574","LU1794554557.SGD","IE00B543WZ88.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2527292479","title":"Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2527292479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527292479?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:16","pubTimestamp":1744802199,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  entered into three distribution and supply agreements with Interpharma PCL  to commercialize several ophthalmic drugs in Thailand, according to a Wednesday filing with the Hong Kong Exchange.The deals cover NVK002 for myopia progression control, BRIMOCHOL PF for presbyopia, and six generic glaucoma drugs: Bimatoprost, Bimatoprost Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol.Under the agreements, Interpharma gains exclusive rights to import, distribute, market, and sell Zhaoke's products in Thailand and will manage local drug registrations. Zhaoke will then receive non-refundable upfront payments and milestone-based payments.Shares of Interpharma closed nearly 5% higher on Wednesday, while those of Zhaoke slipped 3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1587","BK1191","BK1574","06622"],"gpt_icon":0},{"id":"2527635295","title":"BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2527635295","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527635295?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:29","pubTimestamp":1744799368,"startTime":"0","endTime":"0","summary":"BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With InterpharmaApril 16  - Zhaoke Ophthalmology Ltd 6622.HK:ENTERS 3 DISTRIBUTION AGREEMENTS WITH INTERPHARMA TO COMMERCIALIZE NVK002, BRIMOCHO TM PF & 6 GLAUCOMA DRUGS IN THAILANDFurther company coverage: 6622.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06622","BK1191","BK1583"],"gpt_icon":0},{"id":"2527226538","title":"Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2527226538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527226538?lang=en_us&edition=fundamental","pubTime":"2025-04-16 17:07","pubTimestamp":1744794421,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1583","06622","BK1191","BK1574"],"gpt_icon":0},{"id":"2527159664","title":"Peijia Medical's TaurusTrio TAV System Gets Approval for Registration in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2527159664","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527159664?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:33","pubTimestamp":1744720432,"startTime":"0","endTime":"0","summary":"Peijia Medical 's registration application for the TaurusTrio Transcatheter Aortic Valve  system has been accepted by China's National Medical Products Administration, a Monday filing with the Hong Kong bourse said.The TaurusTrio TAV system, which is developed and manufactured by the company based on the exclusive license obtained from JenaValve Technology, is designed to treat patients with native symptomatic severe aortic regurgitation through transfemoral access.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1583","BK1100","09996"],"gpt_icon":0},{"id":"2527852192","title":"Peijia Medical Says NMPA Accepted Registration Application For TaurustrioTM TAV System","url":"https://stock-news.laohu8.com/highlight/detail?id=2527852192","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527852192?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:44","pubTimestamp":1744645495,"startTime":"0","endTime":"0","summary":"April 14 (Reuters) - Peijia Medical Ltd <9996.HK>::*REGISTRATION APPLICATION FOR TAURUSTRIOTM TRANSCATHETER AORTIC VALVE SYSTEM ACCEPTED BY NMPA*Further company coverage: 9996.HK* ((Reuters.Briefs@tho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nRSD6LR8VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","09996","BK1583"],"gpt_icon":0},{"id":"2526803896","title":"HBM Plans Up to HK$200 Million Share Buyback; Shares Surge 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526803896","media":"MT Newswires Live","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526803896?lang=en_us&edition=fundamental","pubTime":"2025-04-11 15:50","pubTimestamp":1744357855,"startTime":"0","endTime":"0","summary":"HBM  plans to repurchase up to HK$200 million of shares under a buyback mandate, according to a Thursday filing with the Hong Kong bourse.The drug company has so far allocated HK$240 million for share buybacks in 2025 on a year-to-date basis, the filing said.Shares surged 12% during Friday's afternoon trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2526830116","title":"Is TOT BIOPHARM International (HKG:1875) A Risky Investment?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526830116","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526830116?lang=en_us&edition=fundamental","pubTime":"2025-04-11 07:14","pubTimestamp":1744326879,"startTime":"0","endTime":"0","summary":"David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1875/tot-biopharm-international-shares/news/is-tot-biopharm-international-hkg1875-a-risky-investment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","01875","BK1574","EBIT"],"gpt_icon":0},{"id":"2526597191","title":"BRIEF-HBM Holdings Intends To Repurchase Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2526597191","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526597191?lang=en_us&edition=fundamental","pubTime":"2025-04-10 23:33","pubTimestamp":1744299194,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Intends To Repurchase Shares Of CoApril 10 (Reuters) - Hbm Holdings Ltd 2142.HK:INTENDS TO REPURCHASE SHARES OF CO IN OPEN MARKET FROM TIME TO TIME UP TO HK$200 MILLIONFurther company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"gpt_icon":0},{"id":"2526556200","title":"Hbm Holdings -  Intends to Repurchase Shares of Co in Open Market From Time to Time up to HK$200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2526556200","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526556200?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:29","pubTimestamp":1744291797,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","BK1161","02142"],"gpt_icon":0},{"id":"2526559026","title":"Peijia Medical Gets China Nod for Registration of YonFlow Stent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559026","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559026?lang=en_us&edition=fundamental","pubTime":"2025-04-10 18:53","pubTimestamp":1744282385,"startTime":"0","endTime":"0","summary":"Peijia Medical  obtained registration approval for the YonFlow Flow Diverting Stent from China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.YonFlow Flow Diverting Stent has been developed by Jiangsu NowYon Medical.Peijia Medical entered into an exclusive distribution agreement with NowYon Medical in August 2024 to sell and distribute the product in Greater China.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","09996","BK1100","BK1574"],"gpt_icon":0},{"id":"2526637338","title":"Harbour Biomed Appoints Youchen Chen as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526637338","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526637338?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:00","pubTimestamp":1744250405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA6Z4B35:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2526839941","title":"BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of Stent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526839941","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526839941?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:27","pubTimestamp":1744212434,"startTime":"0","endTime":"0","summary":"BRIEF-Peijia Medical Gets NMPA Approval For Registration Application Of StentApril 9 (Reuters) - Peijia Medical Ltd 9996.HK:NMPA APPROVAL FOR REGISTRATION APPLICATION OF YONFLOW FLOW DIVERTING STENTFurther company coverage: 9996.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM25R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1574","BK1583","BK1100"],"gpt_icon":0},{"id":"2526352447","title":"Suzhou Basecare Medical Gets Jiangsu Nod for Registration of Sperm Quality Analyzer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526352447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526352447?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:13","pubTimestamp":1744197223,"startTime":"0","endTime":"0","summary":"Suzhou Basecare Medical  obtained registration approval for its portable sperm quality analyzer from Jiangsu Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.The device is a consumer-oriented home-based live sperm detection device designed for male reproductive health.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1222","BK1597","02170"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}]}}